---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061842"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:38:26.666050+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# ARS Pharma discloses $228M cash; neffy investor day presentation published

## Summary
- Cash and short-term investments of ~$228M as of December 31, 2023.
- Updated corporate presentation for neffy (epinephrine nasal spray) shared with investors.
- No additional financial results or forward guidance provided in the 8-K.

## SEC filing metadata
- accession: 0001193125-24-061842
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312524061842/0001193125-24-061842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312524061842/d809686d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061842
- JSON: https://secwatch.observer/filing/0001193125-24-061842.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.